Two-drug ART with dolutegravir-lamivudine would be cost-effective and achieve substantial cash savings
Two-drug maintenance therapy keeps viral load suppressed and may even have advantages over traditional ART
HIV maturation inhibitor BMS-955176 shows good safety and efficacy in phase 2a trial
Tenofovir alafenamide single-tablet regimen shows good efficacy with improved kidney and bone safety
Can dolutegravir dual therapy or monotherapy produce and maintain HIV suppression?
Studies continue to support tenofovir alafenamide combination pill as it nears US approval
HIV attachment inhibitor BMS-663068 matches atazanavir in phase 2b study
New antiretrovirals and HIV treatment strategies highlighted at ICAAC
Switching to new tenofovir alafenamide keeps virus in check and improves kidney and bone health
